Tirzepatide is a novel dual GIP/GLP-1 receptor agonist. This medication has shown promising results in clinical trials for the treatment of type 2 diabetes. By targeting both the GIP and GLP-1 receptors, tirzepatide successfully improves insulin sensitivity. The dual mechanism of action of tirzepatide offers numerous potential benefits over tradit